WolverHeme Happy Hour Episode (3+)7: Straight Outta Roswell - OG AML Data
23 snips
Oct 7, 2022 After a refreshing break, the hosts dive into the fascinating pharmacology behind major AML therapies. They discuss the iconic '3 plus 7' chemotherapy regimen and its lasting impact. Historical insights on anthracyclines reveal their evolution and crucial studies on effectiveness. The conversation also covers the unique journey of cytarabine, exploring its origins and complex administration challenges. Lastly, advancements in purine analogs shed light on new treatment strategies, especially for older patients. Beverages and personal anecdotes add a fun twist to the serious topics!
AI Snips
Chapters
Transcript
Episode notes
Refocusing on AML Basics
- Bernie shares their plan to revisit foundational AML drug pharmacology as groundwork for future discussions.
- They plan to address clinical scenarios including how they treat different AML subtypes with expert guests.
7+3 Endures Over Decades
- The 7+3 chemotherapy regimen for AML was first published in 1973 and remains the backbone treatment nearly 50 years later.
- Despite numerous attempts to improve it, no regimen has reliably surpassed this standard.
Origins of Doxorubicin
- The anthracycline doxorubicin, called the "red devil," originated from an Italian Streptomyces strain and differs from daunorubicin by one hydroxyl group.
- Its name comes from the Adriatic Sea near where it was isolated, reflecting fascinating international pharmaceutical history.